DNA Mugshots

Hologic has named Eric Compton to the newly-established position of chief operating officer. He most recently served as worldwide president of Johnson & Johnson's Ortho Clinical Diagnostics business. Hologic also named Claus Egstrand its new senior VP and general manager, international. He previously held senior positions at Merck, Stryker, Pfizer Consumer Healthcare, and Pharmacia. In addition, David Harding, who previously served as Hologic's group senior VP and GM of women's health, has been named senior VP of corporate strategy. CFO Glenn Muir, who began serving in that post in 1992, will retire from the firm at the end of November.

SISCAPA Assay Technologies has named Selena Larkin its vice president of marketing and sales. Larkin joins the mass spec assay firm after recently serving as global director of pharmaceutical strategy at Agilent Technologies. She previously held positions at Applied Biosystems/Sciex and Irvine Scientific.

Sequenom announced this week that CEO Harry Hixson plans to retire from that position in June, at the time of the company's stockholder meeting. Current President and Chief Operating Officer William Welch will assume Hixson's position upon his retirement. Hixson will continue to serve as chairman of the firm's board of directors, a title he has held since 2003. Welch also will be nominated to serve on the board at the annual meeting, Sequenom said. Also, CFO Paul Maier also will retire from his job in June, but will continue to work with the company as a consultant. Current VP and Chief Accounting Officer Carolyn Beaver will replace Maier as CFO upon his retirement. She previously was corporate VP and controller of Beckman Coulter. In addition, Dirk van den Boom will be promoted to be chief scientific and strategy officer. He has been with Sequenom since 1998, and he recently was the company's executive VP of R&D and chief technology officer.

Former Life Technologies executive Paul Grossman has joined Telegraph Hill Partners as a venture partner. Grossman previously was head of global strategy and corporate development at Life Tech, and he also held the same position at Invitrogen. Before he joined Invitrogen, Grossman held a variety of leadership roles at Applied Biosystems, including as a research scientist and patent attorney, VP of intellectual property, and VP of strategy and business development.

See the original post here:
DNA Mugshots